Amgen Inc. (NASDAQ:AMGN) Shares Sold by Csenge Advisory Group

Csenge Advisory Group cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,139 shares of the medical research company's stock after selling 938 shares during the quarter. Csenge Advisory Group's holdings in Amgen were worth $1,600,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Lansing Street Advisors lifted its position in Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock worth $832,000 after buying an additional 32 shares during the period. Unionview LLC lifted its position in Amgen by 3.8% during the third quarter. Unionview LLC now owns 876 shares of the medical research company's stock worth $282,000 after buying an additional 32 shares during the period. AM Investment Strategies LLC lifted its position in Amgen by 0.4% during the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company's stock worth $2,407,000 after buying an additional 33 shares during the period. Avidian Wealth Enterprises LLC increased its stake in Amgen by 0.6% during the third quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company's stock worth $1,889,000 after acquiring an additional 33 shares during the last quarter. Finally, Beacon Financial Advisory LLC increased its stake in Amgen by 4.6% during the third quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company's stock worth $248,000 after acquiring an additional 34 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 8,771 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the sale, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 35,405 shares of company stock valued at $10,410,596. Insiders own 0.69% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN traded up $3.66 during trading hours on Thursday, reaching $297.93. 2,318,955 shares of the stock were exchanged, compared to its average volume of 3,120,625. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a 50 day simple moving average of $275.15 and a 200-day simple moving average of $300.77. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock has a market capitalization of $160.05 billion, a P/E ratio of 39.46, a P/E/G ratio of 2.54 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, sell-side analysts forecast that Amgen Inc. will post 20.6 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.20%. Amgen's dividend payout ratio (DPR) is 126.09%.

Wall Street Analyst Weigh In

AMGN has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. StockNews.com lowered Amgen from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, December 18th. Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Royal Bank of Canada restated an "outperform" rating and set a $324.00 price target on shares of Amgen in a research note on Friday, January 24th. Finally, Leerink Partners dropped their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has an average rating of "Hold" and an average target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.